Several studies have recently revealed MYC/BCL2/BCL6 rearrangements and TP53 mutations as independent indicators of prognosis in patients with DLBCL treated with standard chemotherapy. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.